Iisrael - heebrea - Ministry of Health

medison pharma ltd - natalizumab - תרכיז להכנת תמיסה לאינפוזיה - natalizumab 300 mg / 15 ml - natalizumab - natalizumab - tysabri is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis . to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations. the safety and efficacy of tysabri beyond two years are unknown. because tysabri increases the risk of progressive multifocal leukoencephalopathy (pml), an opportunistic viral infection of the brain that usually leads to death or severe disability. tysabri is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, alternate multiple sclerosis therapies. safety and efficacy in patients with chronic progressive multiple sclerosis have not been studied.

Iisrael - heebrea - Ministry of Health

abbvie biopharmaceuticals ltd, israel - botulinum toxin type a - אבקה להכנת תמיסה לזריקה - botulinum toxin type a 100 u/vial - botulinum toxin - botulinum toxin - botox is indicated for the symptomatic relief of blepharospasm or vii nerve disorders in patients over 12 years hemifacial spasm and associated focal dystonias as well as the correction of strabismus in patients 12 years of age and above. botox is also indicated for the reduction of the signs and symptoms of spasmodic torticollis ( cervical dystonia) in adults. botox is also indicated for the treatment of dynamic equinus foot deformity due to spasticity in paediatric cerebral palsy patients two years of age or older. focal upper limb spasticity associated with stroke. botox is indicated also for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients aged 65 years or less. management of primary axillary hyperhidrosis in patients who failed other medical symptomatic treatment.symptom relief in adults fulfilling criteria for chronic migraine (headaches on ?15 days per month of which at least 8 days with migrai

Iisrael - heebrea - Ministry of Health

abbvie biopharmaceuticals ltd, israel - botulinum toxin type a - אבקה להכנת תמיסה לזריקה - botulinum toxin type a 50 u/vial - botulinum toxin - botulinum toxin - botox is indicated for the symptomatic relief of blepharospasm or vii nerve disorders in patients over 12 years hemifacial spasm and associated focal dystonias as well as the correction of strabismus in patients 12 years of age and above. botox is also indicated for the reduction of the signs and symptoms of spasmodic torticollis ( cervical dystonia) in adults. botox is also indicated for the treatment of dynamic equinus foot deformity due to spasticity in paediatric cerebral palsy patients two years of age or older. focal upper limb spasticity associated with stroke. botox is indicated also for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients aged 65 years or less. management of primary axillary hyperhidrosis in patients who failed other medical symptomatic treatment.symptom relief in adults fulfilling criteria for chronic migraine (headaches on ?15 days per month of which at least 8 days with migrai

Iisrael - heebrea - Ministry of Health

abbvie biopharmaceuticals ltd, israel - botulinum toxin type a - אבקה להכנת תמיסה לזריקה - botulinum toxin type a 200 u/vial - botulinum toxin - botulinum toxin - botox is indicated for the symptomatic relief of blepharospasm or vii nerve disorders in patients over 12 years hemifacial spasm and associated focal dystonias as well as the correction of strabismus in patients 12 years of age and above. botox is also indicated for the reduction of the signs and symptoms of spasmodic torticollis ( cervical dystonia) in adults. botox is also indicated for the treatment of dynamic equinus foot deformity due to spasticity in paediatric cerebral palsy patients two years of age or older. focal upper limb spasticity associated with stroke. botox is indicated also for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients aged 65 years or less.management of primary axillary hyperhidrosis in patients who failed other medical symptomatic treatment.symptom relief in adults fulfilling criteria for chronic migraine (headaches on ?15 days per month of which at least 8 days with migrain

Iisrael - heebrea - Ministry of Health

megapharm ltd - sulthiame - טבליות מצופות פילם - sulthiame 200 mg - sultiame - sultiame - treatment of epilepsy in adults and in treatment of the so called focal benign epilepsy of children, when other medication was not adequate.

Iisrael - heebrea - Ministry of Health

cartiheal (2009) ltd. - רופא - agili-c implant is a bi-phasic, porous resorbable tissue regeneration scaffold for the treatment of focal articular cartilage and/or osteochondral defects. it is indicated for cartilage and/or bone repair. the implant serves as a scaffold for cellular and matrix ingrowth. the agili-c implant is expected to biodegrade within 6 – 12 months.

Iisrael - heebrea - Ministry of Health

medison pharma ltd - botulinum toxin type a - אבקה להכנת תמיסה לזריקה - botulinum toxin type a 300 u/vial - botulinum toxin

Iisrael - heebrea - Ministry of Health

medison pharma ltd - botulinum toxin type a - אבקה להכנת תמיסה לזריקה - botulinum toxin type a 500 u/vial - botulinum toxin

Iisrael - heebrea - Ministry of Health

trima israel pharmaceutical products maabarot ltd - ciclopirox olamine - תמיסה - ciclopirox olamine 1 % - other antifungals for topical use - broad spectrum antimycotic preparation for topical treatment of fungal infections of the skin.

Iisrael - heebrea - Ministry of Health

abic marketing ltd, israel - epinephrine as bitartrate; lidocaine hydrochloride - תמיסה להזרקה - lidocaine hydrochloride 36 mg / 1.8 ml; epinephrine as bitartrate 22.5 mcg / 1.8 ml - lidocaine, combinations - anesthetics, local - production of local anasthesia by nerve-block infiltration technique.